Diagnosing HCM: What a cardiologist needs to know
Aleš Linhart, MD, PhD
Perspectives on the results of recent clinical outcomes trials with EPA prevention
P. Gabriel Steg, MD
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
Erik Stroes
Pam R. Taub, MD, FACC, FASPC
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Challenges in ASCVD reduction and TG-related risk
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Erin Michos
Oral cholesterol-lowering therapies: The basis of prevention
Lale Tokgözoğlu, MD
The evolving need and challenges to reach LDL-c targets in high-risk patients
Kausik Ray, MBChB, MD, MPhil
PCSK9i: Benefits across the spectrum of cardiovascular disease
Fabrice Martens
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
Stephen Nicholls, FRACP, FACC, FESC, FAHA
John Kastelein, MD, PhD
Roxana Mehran, MD
Unmet needs in lowering LDL-c
New insights on CETP inhibition from genetic research and clinical trials
Exploring the role of a novel CETP inhibitor in lipid management
Hypertrophic cardiomyopathy: What are the concerns?
Antonis Pantazis, MD
Diagnostic challenges for symptomatic obstructive HCM
Pablo García-Pavía, MD, PhD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.